FULGENT GENETICS, INC. Marketable Securities, Gain (Loss)
FULGENT GENETICS, INC. (FLGT) reported Marketable Securities, Gain (Loss) of -$580.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-03.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesGainLoss · last filed 2024-05-03
- FULGENT GENETICS, INC. marketable securities, gain (loss) for the quarter ending 2024-03-31 was -$580.00K.
- FULGENT GENETICS, INC. marketable securities, gain (loss) for the quarter ending 2022-12-31 was -$66.00K.
- FULGENT GENETICS, INC. marketable securities, gain (loss) for the quarter ending 2022-09-30 was -$9.00K.
- FULGENT GENETICS, INC. marketable securities, gain (loss) for the quarter ending 2022-06-30 was -$104.00K.
- FULGENT GENETICS, INC. marketable securities, gain (loss) for fiscal 2023 was -$589.00K.
- FULGENT GENETICS, INC. marketable securities, gain (loss) for fiscal 2022 was -$692.00K.
- FULGENT GENETICS, INC. marketable securities, gain (loss) for fiscal 2021 was -$1.19M.
- FULGENT GENETICS, INC. marketable securities, gain (loss) for fiscal 2020 was -$90.00K.
| Period end | Marketable Securities, Gain (Loss) 3 month | Marketable Securities, Gain (Loss) 6 month | Marketable Securities, Gain (Loss) 9 month | Marketable Securities, Gain (Loss) 12 month |
|---|---|---|---|---|
| 2024-03-31 | -$580.00K 10-Q · filed 2024-05-03 | |||
| 2023-12-31 | -$589.00K 10-K · filed 2024-02-28 | |||
| 2022-12-31 | -$66.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$75.00K derived: sum of 2 quarters · filed 2024-02-28 | -$179.00K derived: sum of 3 quarters · filed 2024-02-28 | -$692.00K 10-K · filed 2024-02-28 |
| 2022-09-30 | -$9.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$113.00K derived: sum of 2 quarters · filed 2023-11-03 | -$626.00K 10-Q · filed 2023-11-03 | -$1.22M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$104.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | -$617.00K 10-Q · filed 2023-08-04 | -$1.21M derived: sum of 3 quarters · filed 2024-02-28 | -$1.44M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | -$513.00K 10-Q · filed 2023-05-05 | -$1.10M derived: sum of 2 quarters · filed 2024-02-28 | -$1.34M derived: sum of 3 quarters · filed 2024-02-28 | -$1.35M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | -$591.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$826.00K derived: sum of 2 quarters · filed 2024-02-28 | -$841.00K derived: sum of 3 quarters · filed 2024-02-28 | -$1.19M 10-K · filed 2024-02-28 |
| 2021-09-30 | -$235.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$250.00K derived: sum of 2 quarters · filed 2022-11-07 | -$595.00K 10-Q · filed 2022-11-07 | |
| 2021-06-30 | -$15.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$360.00K 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | -$345.00K 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | -$90.00K 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |